Business
The subscription period in Dicot Pharma’s rights issue commences today
The subscription period in Dicot Pharma’s rights issue commences today
About this update from Dicot Pharma Ab
Uppsala, Sweden, May 21, 2026. Today, the subscription period commences in Dicot Pharma AB’s (“Dicot Pharma” or the “Company”) rights issue of units consisting of shares and warrants of series TO 7, which was resolved by the Board of Directors on May 8, 2026 (the “Rights Issue”), in which the public also has the opportunity to subscribe for units. The subscription period runs through June 4, 2026. Please note that some nominees and banks may have an earlier deadline for subscription; therefore, shareholders are advised to check with their bank regarding the final date for subscription. The Company also invites to a live company presentation and Q&A session on May 27 at 12:00 CEST.NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION WHERE THE RELEASE, DISTRIBUTION OR PUBLICATION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR REQUIRE ADDITIONAL REGISTRATION OR OTHER MEASURES.Today, May 21, 2026, the subscription period commences in the Rights Issue, which is carried out with the primary purpose of financing the upcoming phase 2b study with the potency treatment candidate LIB-01. The subscription period runs up to and including June 4, 2026. Please note, however, that some nominees and banks may have an earlier deadline for subscribing to the Rights Issue. Subscription is made primarily through the exercise of unit rights received by existing shareholders based on their preferential rights, but shareholders and the public may also subscribe for units without unit rights. Allocation of units subscribed for without preferential rights will be made in accordance with the allocation principles set out in the EU Follow-on Prospectus published by Dicot Pharma on May 19, 2026.By acquiring unit rights, it is possible to subscribe for more than what the preferential rights relating to the original holding entitle to, and anyone who does not intend to exercise their unit rights may sell them in the same way. Trading in unit rights, which entitle holders to subscribe for units with preferential rights, takes place during the period May 21 – June 1, 2026 and is handled by nominees and banks.Please note that certain nominees may close the application period for exercise of unit rights pri...